BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 30, 2026
Home » Authors » John Fox

John Fox

Articles

ARTICLES

Research sheds light on Purkinje neurons

June 11, 2014
By John Fox
HONG KONG – A comprehensive catalogue of proteins manufactured in specific parts of Purkinje neurons that was obtained using sophisticated new techniques may improve the understanding of diseases associated with those cells, such as ataxias and autism, possibly leading to the development of badly needed treatments for such disorders, reported researchers from the Riken Institute in Japan.
Read More

Research sheds more light on Purkinje neurons

June 11, 2014
By John Fox
HONG KONG – A comprehensive catalogue of proteins manufactured in specific parts of Purkinje neurons that was obtained using sophisticated new techniques may improve our understanding of diseases associated with these cells, such as ataxias and autism, possibly leading to the development of badly needed treatments for such disorders, report researchers from the Riken Institute in Japan.
Read More

Afinitor shown to delay tumor growth in HER2+ advanced breast cancer

June 4, 2014
By John Fox
HONG KONG – Adding the oral molecular targeted therapy Afinitor (everolimus, Novartis AG) to conventional chemotherapy plus anti-HER2 treatment reduced the risk of progression of human epidermal growth factor receptor-2 (HER2) positive advanced breast cancer resistant to Herceptin (trastuzumab, Roche AG) by 22 percent and may provide clues to the mechanisms underlying Herceptin resistance, researchers report.
Read More

Afinitor shown to delay tumor growth in HER2+ advanced breast cancer

June 4, 2014
By John Fox
HONG KONG – Adding the oral molecular targeted therapy Afinitor (everolimus, Novartis AG) to conventional chemotherapy plus anti-HER2 treatment reduced the risk of progression of human epidermal growth factor receptor-2 (HER2)-positive advanced breast cancer resistant to Herceptin (trastuzumab, Roche AG) by 22 percent and may provide clues to the mechanisms underlying Herceptin resistance, researchers reported.
Read More

Further doubts cast on purported STAP stem cell technique

May 14, 2014
By John Fox
HONG KONG – Chinese University of Hong Kong (CUHK) researchers reported being unable to replicate controversial research purporting to create stimulus-triggered acquisition of pluripotent (STAP) stem cells, which behave like induced pluripotent stem (iPS) cells, by simple acid-based treatment of somatic cells, suggesting that the method is not as simple or as straightforward as initially claimed.
Read More

Further doubts cast on purported STAP stem cell technique

May 14, 2014
By John Fox
HONG KONG – Chinese University of Hong Kong (CUHK) researchers report being unable to replicate controversial research purporting to create stimulus-triggered acquisition of pluripotent (STAP) stem cells, which behave like induced pluripotent stem (iPS) cells, by simple acid-based treatment of somatic cells, suggesting that the method is not as simple or straightforward as initially claimed.
Read More

Molecular structures are key to blood clotting identified

May 7, 2014
By John Fox
HONG KONG ­– International researchers led by the Shanghai Institute of Materia Medica (SIMM) at the Chinese Academy of Sciences have mapped the detailed structure of a receptor with a key role in platelet activation and blood clotting, which has important implications for development of new treatments for cardiovascular and possibly other diseases.
Read More

Molecular structures are key to blood clotting identified

May 7, 2014
By John Fox
HONG KONG ­– International researchers led by the Shanghai Institute of Materia Medica (SIMM) at the Chinese Academy of Sciences have mapped the detailed structure of a receptor with a key role in platelet activation and blood clotting, which has important implications for development of new treatments for cardiovascular and possibly other diseases.
Read More

Xarelto more effective than warfarin for stroke prevention in Asian AF

May 5, 2014
By John Fox
HONG KONG – The oral anticoagulant Xarelto (rivaroxaban, Johnson & Johnson) is more effective than warfarin for preventing stroke and intracranial hemorrhage (ICH), particularly in Asian patients with atrial fibrillation (AF), Chinese University of Hong Kong (CUHK) scientists have reported.
Read More

New mouse models may revolutionize Alzheimer's research

April 16, 2014
By John Fox
HONG KONG — The creation of two new genetically modified mouse models of Alzheimer's disease by Japanese neuroscientists could revolutionize research into the debilitating neurodegenerative disease and lead to the development of badly needed new treatments.
Read More
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing